File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Loss/down-regulation of tumor suppressor in lung cancer 1 expression is associated with tumor progression and is a biomarker of poor prognosis in ovarian carcinoma

TitleLoss/down-regulation of tumor suppressor in lung cancer 1 expression is associated with tumor progression and is a biomarker of poor prognosis in ovarian carcinoma
Authors
KeywordsImmunohistochemistry
Ovarian tumor
Prognosis
TSLC1
Issue Date2011
PublisherLippincott Williams & Wilkins. The Journal's web site is located at tp://www.ijgc.net/
Citation
International Journal Of Gynecological Cancer, 2011, v. 21 n. 3, p. 486-493 How to Cite?
AbstractObjectives: The tumor suppressor in lung cancer 1 (TSLC1) has been identified as a putative tumor suppressor gene in non-small cell lung cancer. Although loss of TSLC1 has been observed in a number of human malignancies, the expression levels of TSLC1 gene in ovarian cancer and its clinical or prognostic significance have not been investigated. Methods: Protein expression levels of TSLC1 was explored by semiquantitative immunohistochemical staining on archival formalin-fixed, paraffin-embedded pathological specimen consisting of 30 normal ovaries, 30 ovarian cystadenomas, 40 borderline ovarian tumors, and 160 invasive ovarian carcinomas. The TSLC1 immunohistochemical staining results were then correlated with various clinicopathologic parameters and patient prognosis using various statistical models. Results: Significantly decreased, or complete loss of, protein expression of the TSLC1 gene was observed in 59%ovarian carcinomas, 45% borderline tumors, and 7% cystadenomas, but in none of the normal ovaries (0%). In ovarian carcinomas, decreased TSLC1 expression was significantly correlated with lymph node metastasis (pN, P = 0.001), distant metastasis (pM, P = 0.028), and more advanced International Federation of Gynecology and Obstetrics stages (P = 0.008). By univariate survival analysis on the ovarian carcinoma cohorts, decreased TSLC1 protein expression was significantly associated with shortened patient survival (mean: 26.9 months in tumors with complete loss of TSLC1 vs 63.1 months in tumors with significantly decreased TSLC1 vs 94.3 months in tumors with normal levels of TSLC1; P < 0.001). By multivariate analysis, TSLC1 protein expression remained as a significant and independent prognostic factor for the prediction of patient survival (P = 0.003). Conclusions: Decreased protein expression of the TSLC1 gene might be important in conferring a more aggressive behavior in ovarian carcinoma. Thus, TSLC1 may be used as an independent prognostic molecular marker for patients with ovarian carcinoma. Copyright © 2011 by IGCS and ESGO.
Persistent Identifierhttp://hdl.handle.net/10722/137271
ISSN
2014 Impact Factor: 1.958
2014 SCImago Journal Rankings: 0.750
ISI Accession Number ID
Funding AgencyGrant Number
Nature Science Foundation of China30772334
973 Project of China2010CB912802
2010CB529401
Guangdong Science and Technology Agency2004B35001004
Funding Information:

This study was supported by the grants from the Nature Science Foundation of China (no. 30772334), the 973 Project of China (no. 2010CB912802 and 2010CB529401), and Project of Guangdong Science and Technology Agency (no. 2004B35001004).

References

 

DC FieldValueLanguage
dc.contributor.authorYang, Gen_HK
dc.contributor.authorHe, Wen_HK
dc.contributor.authorCai, Men_HK
dc.contributor.authorLuo, Fen_HK
dc.contributor.authorKung, Hen_HK
dc.contributor.authorGuan, Xen_HK
dc.contributor.authorZeng, Yen_HK
dc.contributor.authorXie, Den_HK
dc.date.accessioned2011-08-26T14:22:13Z-
dc.date.available2011-08-26T14:22:13Z-
dc.date.issued2011en_HK
dc.identifier.citationInternational Journal Of Gynecological Cancer, 2011, v. 21 n. 3, p. 486-493en_HK
dc.identifier.issn1048-891Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/137271-
dc.description.abstractObjectives: The tumor suppressor in lung cancer 1 (TSLC1) has been identified as a putative tumor suppressor gene in non-small cell lung cancer. Although loss of TSLC1 has been observed in a number of human malignancies, the expression levels of TSLC1 gene in ovarian cancer and its clinical or prognostic significance have not been investigated. Methods: Protein expression levels of TSLC1 was explored by semiquantitative immunohistochemical staining on archival formalin-fixed, paraffin-embedded pathological specimen consisting of 30 normal ovaries, 30 ovarian cystadenomas, 40 borderline ovarian tumors, and 160 invasive ovarian carcinomas. The TSLC1 immunohistochemical staining results were then correlated with various clinicopathologic parameters and patient prognosis using various statistical models. Results: Significantly decreased, or complete loss of, protein expression of the TSLC1 gene was observed in 59%ovarian carcinomas, 45% borderline tumors, and 7% cystadenomas, but in none of the normal ovaries (0%). In ovarian carcinomas, decreased TSLC1 expression was significantly correlated with lymph node metastasis (pN, P = 0.001), distant metastasis (pM, P = 0.028), and more advanced International Federation of Gynecology and Obstetrics stages (P = 0.008). By univariate survival analysis on the ovarian carcinoma cohorts, decreased TSLC1 protein expression was significantly associated with shortened patient survival (mean: 26.9 months in tumors with complete loss of TSLC1 vs 63.1 months in tumors with significantly decreased TSLC1 vs 94.3 months in tumors with normal levels of TSLC1; P < 0.001). By multivariate analysis, TSLC1 protein expression remained as a significant and independent prognostic factor for the prediction of patient survival (P = 0.003). Conclusions: Decreased protein expression of the TSLC1 gene might be important in conferring a more aggressive behavior in ovarian carcinoma. Thus, TSLC1 may be used as an independent prognostic molecular marker for patients with ovarian carcinoma. Copyright © 2011 by IGCS and ESGO.en_HK
dc.languageengen_US
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at tp://www.ijgc.net/en_HK
dc.relation.ispartofInternational Journal of Gynecological Canceren_HK
dc.subjectImmunohistochemistryen_HK
dc.subjectOvarian tumoren_HK
dc.subjectPrognosisen_HK
dc.subjectTSLC1en_HK
dc.subject.meshAdenocarcinoma, Mucinous - metabolism - pathology-
dc.subject.meshCell Adhesion Molecules - metabolism-
dc.subject.meshCystadenocarcinoma, Serous - metabolism - pathology-
dc.subject.meshImmunoglobulins - metabolism-
dc.subject.meshOvarian Neoplasms - metabolism - pathology-
dc.titleLoss/down-regulation of tumor suppressor in lung cancer 1 expression is associated with tumor progression and is a biomarker of poor prognosis in ovarian carcinomaen_HK
dc.typeArticleen_HK
dc.identifier.emailGuan, X:xyguan@hkucc.hku.hken_HK
dc.identifier.authorityGuan, X=rp00454en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1097/IGC.0b013e31820fa168en_HK
dc.identifier.pmid21436696-
dc.identifier.scopuseid_2-s2.0-80051647936en_HK
dc.identifier.hkuros190875en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-80051647936&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume21en_HK
dc.identifier.issue3en_HK
dc.identifier.spage486en_HK
dc.identifier.epage493en_HK
dc.identifier.isiWOS:000288743700011-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridYang, G=16064823400en_HK
dc.identifier.scopusauthoridHe, W=35185088700en_HK
dc.identifier.scopusauthoridCai, M=23388510500en_HK
dc.identifier.scopusauthoridLuo, F=49061297000en_HK
dc.identifier.scopusauthoridKung, H=7402514190en_HK
dc.identifier.scopusauthoridGuan, X=7201463221en_HK
dc.identifier.scopusauthoridZeng, Y=49061648500en_HK
dc.identifier.scopusauthoridXie, D=35070710200en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats